Shanghai Rightongene Biotechnology

Shanghai Rightongene Biotechnology is a leading Chinese life sciences company specializing in the development, manufacturing, and commercialization of in vitro diagnostic (IVD) products for precision medicine. Founded in 2012 and headquartered in Shanghai, the company focuses on precision oncology, including leukemia subtyping, minimal residual disease (MRD) monitoring, and early cancer screening. Its extensive product portfolio includes molecular diagnostic kits for leukemia-associated fusion genes, solid tumor mutations such as EGFR and KRAS, and various infectious diseases. Rightongene is publicly traded on the Shanghai Stock Exchange's STAR Market and maintains strategic international partnerships, notably with Otsuka Pharmaceutical. The company's technological capabilities encompass PCR, next-generation sequencing (NGS), and digital PCR, positioning it as a key player in China's precision healthcare landscape.